Visualizar Tese - Instituto de Biociências - Unesp

REFERENCES[1] Baird DD, Dunson DB (2003) Why is parity protective for uterine fibroids? Epidemology14: 247-250.[2] Mantovani MS, Barbieri Neto J, Philbert PMP (1999) Multiple uterine leiomyomas:Cytogenetic analysis. Gynecol Oncol 72: 71–75.[3] Cook H, Ezzati M, Segars JH et al. (2010) The impact of uterine leiomyomas onreproductive outcomes. Minerva Ginecol 62: 225-236.[4] Flake GP, Andersen J, Dixon D (2003) Etiology and pathogenesis of uterine leiomyomas:a review. Environ Health Perspect 111: 1037-1054.[5] Ishikawa H, Ishi K, Serna VA et al. (2010) Progesterone is essential for maintenance andgrowth of uterine leiomyoma. Endocrinology 151:2433-2442.[6] Sozen I and Arici A (2002) Interactions of cytokines, growth factors, and the extracellularmatrix in the cellular biology of uterine leiomyomata. Fertil Steril 78: 1-12.[7] Marsh EE, Lin Z, Yin P, Milad M et al. (2008) Differential expression of microRNAspecies in human uterine leiomyoma versus normal myometrium. Fertil Steril 89: 1771-1776.[8] Bonatz G, Frahm SO, Andreas S et al. (1998) Telomere shortening in uterine leiomyomas.Am J Obstet Gynecol 179: 591-596.[9] Malik M, Norian J, McCarthy-Keith D et al. (2010) Why leiomyomas are called fibroids:the central role of extracellular matrix in symptomatic women. Semin Reprod Med 28: 169–179.[10] Canevari RA, Pontes A, Rogatto SR (2005) Microallelotyping Defines Novel Regions ofLoss of Heterozygosity in Uterine Leiomyomas. Mol Carcinog 42: 177–182.[11] Canevari, RA and Rogatto SR (2007) Uterine Leiomyoma: Updates in Cytogenetics andMolecular Analysis. Asian Journal of Cancer 6: 15-28.[12] El-Gharib MN and Elsobky ES (2010) Cytogenetic aberrations and the development ofuterine leiomyomata. J Obstet Gynaecol Res 36: 101–107.[13] Arslan AA, Gold LI, Mittal K et al. (2005) Gene expression studies provide clues to thepathogenesis of uterine leiomyoma: new evidence and a systematic review. HumanReproduction 20: 852-863.[14] Quade BJ, Wang TY, Sornberger K et al. (2004) Molecular pathogenesis of uterinesmooth muscle tumors from transcriptional profiling. Genes Chrom Cancer 40: 97–108.[15] Vanharanta S, Wortham NC, Laiho P et al. (2005) 7q deletion mapping and expressionprofiling in uterine fibroids. Oncogene 24: 6545-6554.[16] Hodge JC, Park PJ, Dreyfuss JM et al. (2009) Identifying the molecular signature of theinterstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis. Genes ChromCancer 48: 865–885.[17] Akavia UD, Litvin O, Kim J et al. (2010) An integrated approach to uncover drivers ofcancer. Cell 143: 1005–1017.[18] Staaf J, Jönsson G, Ringnér M et al. (2010) High-resolution genomic and expressionanalyses of copy number alterations in HER2-amplified breast cancer. Breast CancerResearch, 12: R25.16